Trial Profile
A Phase II, Double-blind, Randomized, Proof-of-Concept, Dose-ranging Trial Evaluating the Efficacy, Safety and Pharmacokinetics of Oral LDE225 in Treatment of Adult Patients With Nevoid Basal Cell Carcinoma Syndrome
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 18 Jun 2021
Price :
$35
*
At a glance
- Drugs Sonidegib (Primary)
- Indications Basal cell nevus syndrome
- Focus Proof of concept; Therapeutic Use
- Sponsors Novartis Pharmaceuticals Corporation
- 25 Apr 2021 Results secondary analysis on the long-term impact of 12 weeks of sonidegib treatment on the size and number of NBCCS, presented at the American Academy of Dermatology Virtual Meeting Experience 2021.
- 25 Apr 2021 Results evaluating the pharmacokinetics of sonidegib in patients with NBCCS, presented at the American Academy of Dermatology Virtual Meeting Experience 2021
- 23 Sep 2016 Results of pooled analysis of this and other three studies on patients and four on volunteers published in the European Journal of Clinical Pharmacology (2016).